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INTRODUCTION
With prevalence rates of 10% to 20% of the population, tinnitus represents a major
global burden.1,2 Tinnitus prevalence grows with age and has increased in the past de-
cades,3 presumably owing to an increased exposure to loud sounds. Although most
patients can cope adequately with their tinnitus, nearly 1 out of 10 (ie, in 2%–3% of
the total population) experiences severe tinnitus4 that can be accompanied by frustra-
tion, annoyance, anxiety, depression, cognitive dysfunction, insomnia, stress, and
emotional exhaustion—all of which lead to a substantial decrease in quality of life5,6
and an enormous socioeconomic burden.7
The available treatment options for tinnitus are limited. Cognitive behavioral therapy
(CBT) is helpful for reducing tinnitus annoyance and tinnitus handicap, but there exists
no established treatment that has shown evidence in randomized controlled studies to
reduce tinnitus loudness. Thus, given the high prevalence and the enormous socio-
economic relevance, there is an urgent need to develop better treatment options for
tinnitus.
This article first provides a short overview about recent advances in the understand-
ing of the pathophysiology of tinnitus, because this provides the basis for the
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development of new treatments. There exist several challenges in the development
of new treatments, and how these can be addressed is discussed. Then, current
research activities in neuromodulation, auditory treatments, pharmacotherapy,
eHealth, and patient involvement are summarized before what might be needed to
attract more private and public funding in the tinnitus field is discussed.
CURRENT KNOWLEDGE OF THE PATHOPHYSIOLOGY OF TINNITUS
In recent decades, knowledge about the pathogenesis of tinnitus has increased
massively. Although there is no complete consensus among experts, the dominant
opinion is that tinnitus is preceded by peripheral hearing loss. Often the affected per-
son describes a hearing sensation that lies in a frequency range that is congruent with
the frequency range of the hearing loss.8 After peripheral hearing loss due to partial
damage of the hair cells in the inner ear, the transmission of stimuli from the cochlea
to the auditory cortex in the brain is interrupted.9 Because of this sensory deprivation,
an increased synchronicity of the spontaneous activity of the neurons in the auditory
cortex, which represents the corresponding frequency ranges, is observed.10 A weak-
ening of the intracortical balance of excitation and inhibition leads to a reorganization
of the architecture of the auditory cortex, resulting in new ensembles of nerve cells that
have changed their frequency specificity.11 If the synchronous activity of these nerve
cell clusters continues undiminished for some time, the affected personsmay perceive
an ear noise with different characteristics and variable loudness and duration. Whether
this maladaptive phenomenon leads to tinnitus perception at all and to what extent it is
pronounced in terms of personal aversiveness, loudness, or accompanying symp-
toms, such as sleep disorders, anxiety, panic, and stress, depend on coactivation
of nonauditory brain networks.12,13 These networks include limbic, insular, parahippo-
campal, frontal, and parietal structures.14 In the context of this more generally formu-
lated idea on the pathogenesis of tinnitus, several models exist that give more or less
weight to certain aspects of network theory.11,15–17 These are not discussed in detail.
It must be seen as a decisive moment of the modern models for the genesis of tinnitus
that it is no longer the periphery with the ear structures or the auditory nerve that is in
the foreground but the neuroplastic changes in central nervous structures that occur
as a consequence of peripheral deafferentation. Furthermore, it has been shown that
neural connections between the auditory and somatosensory systems located at the
dorsal cochlear nucleus play a role in tinnitus perception as well.18 In particular, the
ability of some affected individuals to modulate the tinnitus sound through somatic
maneuvers is at stake.
All these new insights have changed the focus with regard to potential therapies. For
2 decades, methods have been under discussion in research, which take into account
the central aspects of tinnitus genesis, such as neuromodulation, the neural connec-
tions between the somatosensory and auditory systems, and pharmacotherapy of
centrally acting neurotransmitters.
CURRENT CHALLENGES IN THE DEVELOPMENT OF NEW TREATMENTS
Based on current knowledge, that tinnitus results from functional changes of neuronal
activity, there exists no reason to believe that tinnitus cannot be efficiently treated
either by neuromodulation or by pharmacotherapy. But why do effective treatments
for tinnitus not exist?
There are several reasons that can explain why the development of effective treat-
ments for tinnitus is so difficult.19
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From a historical perspective, the development of treatments for brain disorders
was driven by serendipitous discoveries. Apart from lidocaine, such serendipitous dis-
coveries are lacking in the tinnitus field, and lidocaine cannot be applied regularly
because of its side effects nor can other drugs with a comparable effect be identified.
Moreover, because no exact drug target is known that reliably reduces tinnitus, there
also do not exist in vitro bioassays for high-throughput screening of pharmacologic
compounds.20
Animal models have been developed but have limitations.21 Further challenges for
the development of new compounds are the heterogeneity of tinnitus and its subjec-
tive nature, which make tinnitus assessment difficult.
Limitations of Available Animal Models of Tinnitus
For the development of a valid animal model of tinnitus, it is necessary to develop
methods for both reliable tinnitus induction and assessment. Two different ap-
proaches are used to generate tinnitus: first, the systemic administration of ototoxic
drugs, such as salicylate or quinine; and second, the exposure to loud noise. These
two methods induce tinnitus via different mechanisms, with the latter probably more
similar to the clinical situation.
Assessment of tinnitus typically has been performed indirectly by measuring behav-
ioral reactions to silence. These behavioral tests require months to train the animals
and, to circumvent this problem, another animal model of tinnitus exploits the acoustic
startle response, which is based on an objective reflex response that does not require
lengthy training sessions.22 The magnitude of the startle reflex in response to, for
example, a loud sound, is reduced when the startling stimulus is preceded by a silent
gap in an otherwise continuous acoustic background. In animals that are noise-
traumatized or salicylate-treated, the inhibition of the startle reflex by the gap is
reduced and this is interpreted as an indication of tinnitus. What exactly is assessed
by these behavioral tests and what modulates the startle response, however, are mat-
ters of debate. The magnitude of the startle response itself can be influenced by hear-
ing loss, hyperacusis, and anxiety. The degree of inhibition caused by gaps also varies
considerably between rodent species. Nevertheless, among animals that all have
been exposed to a similar noise trauma, those that demonstrate behavioral evidence
of tinnitus, as assessed with the Gap-Prepulse Inhibition of the Acoustic Startle Reflex,
show consistent neurophysiologic alterations compared with those that do not.18 An
additional challenge to the use of tinnitus animal models is that, in humans, the phan-
tom sound frequently is accompanied by emotional and cognitive symptoms,14,23
which still are not recapitulated in available animal models.24,25
Challenges in Translating Animal Findings to Humans
The usefulness of available animal models for testing tinnitus treatments is still a mat-
ter of debate, because some treatments, which were successful in animal studies,
failed to show positive effects in humans. For instance, carbamazepine seems to be
efficacious in rats26 but not in humans,27 and the same is true for ginkgo biloba.28
An enriched acoustic environment seems to ameliorate tinnitus in animals29 but not
as much in humans.30 The reported discrepancies between the results from animal
models and human treatment studies do not necessarily mean that animal models
of tinnitus have no predictive value, because inconsistencies also may be related to
limitations in both animal and human studies (eg, methodology, outcomemeasure, eti-
ology, comorbidities, time and duration of the treatment, and sample size). Caution is
warranted, however, in the direct translation of tinnitus animal research to humans,
especially research into novel treatments.
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Tinnitus Heterogeneity
Tinnitus differs across patients in its perceptual characteristics (eg, frequency and in-
tensity), in its time course (constant, fluctuating, and intermittent), response to inter-
ventions (eg, masking sounds and somatic maneuvers), etiologic factors, and
comorbidities. This heterogeneity of tinnitus is reflected by a substantial variability in
tinnitus pathophysiology.13 This means that probably many different forms of tinnitus
exist, which vary in their pathophysiology and their response to a specific treatment
intervention. If patients with different subtypes are included in a clinical trial, a high
variability in the treatment outcome has to be expected. Therefore, a major challenge
in clinical tinnitus research is the identification of reliable subtypes or the identification
of relevant criteria for subtyping patients.31,32 One approach is the development of
large clinical databases for disentangling subgroups of tinnitus.33
Measurement of Tinnitus in Humans
Outcome measurement in clinical trials is complicated by the fact that tinnitus is a
purely subjective phenomenon, for which objective measurements are still missing.
A further difficulty is that perceptual aspects of tinnitus (eg, loudness) do not explain
the subjectively perceived severity of the symptom. Thus, a comprehensive evaluation
of tinnitus has to include the assessment of both perceptual aspects of tinnitus (eg,
loudness and pitch) and of subjective tinnitus severity (eg, tinnitus related functional
impairment or tinnitus handicap). Perceptual aspects can be assessed by psycho-
acoustic methods and subjective rating scales (eg, visual analog scales or numeric
rating scales); tinnitus impairment can be quantified by various validated question-
naires.34,35 Because the different measurements provide complementary information,
current best practice is the use of several outcome measurements in parallel for the
evaluation of treatment-induced changes.36–38 A recent analysis revealed a high vari-
ability in the outcome instruments used in clinical trials,35 indicating the need to stan-
dardize outcome measurement.36,39,40 This is important particularly because
regulatory agencies, such as the Food and Drug Administration (FDA) or European
Medicines Agency lack standardized protocols for their approval process.
NEUROMODULATION
As a consequence of the models for the pathogenesis of tinnitus, described previ-
ously, it seems reasonable to consider a modification of neuronal activity in the areas
of the brain involved in the neuronal circuits responsible for tinnitus. In this way, both
auditory and nonauditory areas can be reached. Essentially, a distinction is made be-
tween invasive and noninvasive neuromodulation. The aim of any method is to
normalize the tinnitus-related brain activity. The increasing improvement of structural
and functional neuroimaging techniques made it possible to more precisely target
those areas of the brain that are mainly responsible for tinnitus perception or the
tinnitus-related distress. Over the past 2 decades, many different methods of neuro-
modulation have been evaluated for their effectiveness in tinnitus control. Noninvasive
methods included repetitive transcranial magnetic stimulation,41–43 transcranial elec-
tric stimulation,44–46 transcutaneous electric nerve stimulation,47,48 and neurofeed-
back.49–51 All techniques have been tested at different institutions and with different
approaches in various studies.52 In the meantime, standardized reviews for the
individual techniques are available.45,53,54 It could be shown that the targeted neuro-
modulation of brain activity leads in certain cases to a reduction of tinnitus or tinnitus-
related complaints.The data regarding long-term effects and complete elimination of
tinnitus by noninvasive neuromodulation have not been achieved. Thus, all of these
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techniques are experimental at this time.52 In this context, it seems of great impor-
tance to make further progress in the better phenotyping of tinnitus and to better un-
derstand which changes in the neuronal networks are the most important in individual
cases. The general trend in noninvasive neuromodulation certainly is also in the direc-
tion of simplifying procedures. Therefore, strategies that could be carried out by those
affected without dependence on complex equipment or a clinical institution, for
example, at home, also are regarded as ideal procedures. First experiments with mo-
bile electroencephalogram systems will focus on, in particular, neurofeedback or
transcranial electric stimulation and transcutaneous electric nerve stimulation proced-
ures for the future.55,56
Invasive neuromodulation procedures involve implanting electrodes extradurally
(epidural), cortically (subdural), or for deep brain stimulation.57 These procedures
were applied experimentally in tinnitus patients, or had effects on tinnitus in patients
undergoing deep brain stimulation for treatment of movement disorders (eg, Parkin-
son disease).58–62 In particular, with regard to deep brain stimulation of the auditory
system (inferior colliculus and medial geniculate body), animal studies currently are
under way to evaluate the significance of direct electrostimulation of the structures,
described previously.63–65 Case reports exist on the use of brain stem implants in
humans, suggesting a positive effect on tinnitus-related complaints.66,67 Due to the
significantly greater invasiveness, the data on invasive neuromodulation are limited..
Nevertheless, there also are reviews that attempt to evaluate the previous studies
as a whole.52,68 The quality of the studies, however, which generally do not exceed
the level of case reports or case series, does not permit a final evaluation at this point
in time. The significant invasiveness of the procedures, however, in conjunction with a
considerable side-effect profile, suggest that such procedures will be considered for
only a very small subgroup of tinnitus patients in the future, if at all.69
In this context of invasive neuromodulation techniques, two procedures that
directly stimulate nerve structures through implanted electrodes, cochlear implan-
tation and vagus nerve stimulation, should be discussed. In particular, cochlear
implantation is a routine procedure that is used for bilateral and now also
single-sided deafness. Multiple studies and reviews have shown that cochlear im-
plantation not only improves hearing but also reduces tinnitus perception in the re-
cipients.70,71 The high suppression rates of tinnitus when the implant is switched
on must be interpreted as an outstanding tinnitus therapy that can certainly sur-
pass the effect of standard procedures. The indication reduced to severe hearing
loss and deafness is considered a limitation. This success suggests, however, that
electric stimulation of peripheral auditory structures can improve tinnitus. The
exact mechanism of action has not yet been clarified. Tinnitus suppression might
be discussed as a direct effect of electric stimulation or as an indirect conse-
quence in the sense of masking with improved hearing. For future scientific ap-
proaches, this represents an approach that already has been applied in
experimental form to single subjects with tinnitus who have normal hearing in
the sense of stimulation of the external auditory canal, the promotorium, or the
round window.72,73 There is great potential for future studies. Because vagus
nerve stimulation in tinnitus is applied in clinical studies in terms of bimodal or
multimodal stimulation, it is discussed subsequently in more detail.
SOMATOSENSORY STIMULATION
An interaction between the auditory and somatosensory system has been demon-
strated on different levels. Auditory and somatosensory input converges already at
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the level of the dorsal cochlear nucleus.18 Further interactions occur at higher brain
levels.74 Clinical reflections of these interactions are the onset of tinnitus after neck
trauma,75 the comorbidity of tinnitus with neck pain and temporomandibular disor-
der,76 and the observation that tinnitus can be modulated by head or neck movements
in a majority of cases.77
These phenomena are summarized by the term, somatosensory tinnitus, but it is
important to note that this term does not describe a clearly defined subtype of tinnitus
but rather the degree of involvement of the somatosensory system in an individual’s
tinnitus. Therefore, somatosensory tinnitus should be viewed as a dimensional rather
than categorical term.78
The involvement of the somatosensory system is the basis for several treatment ap-
proaches. First, if there exist pathologies in the neck area or in the temporomandibular
system, they should be treated, because a normalization of these pathologies can
improve tinnitus.79 Second, treatments, such as transcutaneous electrical stimula-
tion,80 acupuncture, neural therapy, and muscle relaxation,81 have shown promising
results in subgroups of patients.
BIMODAL OR MULTIMODAL STIMULATION
Bimodal or multimodal stimulation presumably is more effective for the induction of
neuroplastic effects than unimodal stimulation. Recently, different approaches of
bimodal or multimodal stimulation have been proposed for the treatment of tinnitus.
A combination of auditory stimulation with vagal stimulation has demonstrated high-
ly impressive results in an animal model of tinnitus.82 Based on the rationale that vagal
stimulation renders the simultaneously presented sounds more salient, the combined
treatment almost completely reversed neurophysiologic and behavioral signs of
tinnitus, which was not the case with auditory stimulation alone. In subsequent human
pilot studies, the efficacy of the treatment could be confirmed albeit the effects were
clearly less pronounced than in animals.83
Another approach explored transcranial direct current stimulation of cortical areas
to facilitate the effects of masking sounds and notched music with only limited
success.84,85
In a recent pilot study, a combination of sounds with transcutaneous electrical stim-
ulation to the neck or the temporomandibular area yielded impressive results. The so-
matosensory and auditory stimuli were presented at specific intervals that were
derived from basic neurophysiologic studies describing stimulus timing–dependent
plasticity in the dorsal cochlear nucleus.86
A combined application of sounds and electrical stimulation of the tongue was
investigated in 2 large trials with results not yet published.87,88 Simultaneous applica-
tion of sounds and electrical stimulation of the tongue afferents may reduce tinnitus by
providing a compensatory input to the partly deafferented central auditory system.
CLINICAL DATABASES
A major limitation with regard to finding a causal therapy for tinnitus lies in the hetero-
geneity of the symptom.32 Thus, the phenomenon of therapeutic procedures that help
1 person but do not work for others reflects a repeated finding. Therefore, it is a great
challenge for a therapist to find out which is the most promising procedure for a spe-
cific patient. Unfortunately, there are no reliable clinical predictors for most proced-
ures that could predict the success of a therapy from the outset. An additional
complicating factor is that most studies evaluating a specific method to improve
tinnitus involve only a small number of cases. The comparability between studies is
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hampered by different methods in tinnitus assessment and in the determination of
therapy outcome. Thus, most standardized reviews come to the conclusion that a
concrete statement on the value of a therapy is difficult or that the quality of the
data is so limited that certain approaches cannot be recommended.19
In order to address these shortcomings, it makes sense that generally accepted
methodological measures are taken into account in studies to improve the compara-
bility of the studies afterward. One possibility is that there would be international da-
tabases in which both data on tinnitus assessment and data on responsiveness to
certain therapies would be entered according to the same pattern. An attempt in
this respect is the database of the Tinnitus Research Initiative.33 The database is
open to all interested therapists and scientists who are willing to contribute patient
data according to the guidelines. After corresponding consensus conferences,36 it
was agreed that certain guidelines should be followed when entering data, such as
the primary tinnitus assessment, using a standardized case report form, or a standard-
ized recording of the success of therapy. In addition, data on hearing ability (pure tone
audiometry), tinnitus matching, or tinnitus severity can be entered according to ques-
tionnaires validated in different languages. This project, established in 2008, currently
comprises more than 4000 data sets on tinnitus patients from more than 10 different
countries (https://www.tinnitusresearch.net/index.php/for-clinicians/database). In
this way it is possible to improve the subtyping of tinnitus by cluster analyses, to iden-
tify subgroups that could respond particularly well to certain treatments, to answer
epidemiologic questions, or to improve the statistical power for certain questions by
pooling data. Such projects are indispensable for future genetic research. Legal and
data privacy issues have to be considered in such projects. Cooperation within the
framework of major research projects financed by the European Union could play
an important pioneering role. In the future, it can be assumed that such database pro-
jects will represent an important step with regard to personalized medicine in the care
of tinnitus patients.
eHealth (APPS AND OTHERS)
eHealth is a highly dynamic research area in medicine and refers to the use of elec-
tronic information and communication technologies for health management. In recent
years, there has been an increasing interest in eHealth technologies for the support of
tinnitus patients. These include tools for patient communication and information,
ecological momentary assessment of tinnitus symptoms, smartphone-based auditory
treatments, Internet-based CBT (iCBT), serious games, and virtual reality applications.
Similar to other medical fields, within a short time a large number of electronic tools
have been developed and are offered in app stores. Most of these tools, however,
have no regulatory approval and a vast majority are not scientifically evaluated.
Counseling is considered the basis of every tinnitus treatment. A majority of tinnitus
patients worldwide, however, do not receive structured counseling according to mod-
ern standards. Thus, information about tinnitus and counseling via the Internet or a
smartphone app represents a feasible and cost-effective option to reach many tinnitus
patients who currently are lacking adequate counseling. An example represents the
Tinnitus E-Programme, which is an Internet-based intervention program that consists
of mainly educational content (ie, about tinnitus or “the role of psychological mecha-
nisms in tinnitus”) and relaxation-focused and attentional-focused exercises.89 The
program has been evaluated and all of the files are accessible for free on a Web
site created for this intervention program [http://www.tinnituseprogramme.org/].90
Several smartphone apps for tinnitus counseling currently are under development.
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eHealth tools also have been developed for assisting diagnosis and assessment of
tinnitus patients. These include Internet-based hearing tests,91,92 tinnitus matching
tools,93,94 and tools for ecological momentary assessment.95,96 Internet-based or
app-based hearing tests and tinnitus matching tools aim at offering audiological mea-
surements for tinnitus patients at low cost, easy availability, and sufficient quality. This
approach is important especially in the context of therapeutic auditory stimulation,
because many innovative auditory stimulation approaches are individualized accord-
ing to a person’s hearing function and tinnitus pitch.
Ecologicalmomentaryassessment incontrastopensupanewquality in tinnitusassess-
ment,because itenables to record fluctuations in tinnitusperceptionandannoyance in real
time.95 This is important because the retrospective assessment of tinnitus fluctuations is
onlyof limited reliability, for example,due toa recall bias.Byassessing tinnitusby repeated
assessment in normal life conditions, these ecological momentary assessment apps
enable real-time assessment of tinnitus fluctuations under normal life conditions. This in-
formation can be used for diagnostic purpose, for counseling, and for CBT. Moreover, it
represents the basis for the development of a closed-loop system that offers therapeutic
interventions exactly at the moment when they are needed or most effective.
iCBT is an approach that delivers CBT via the Internet, either only online-based or in
a blended fashion, that integrates face-to-face and online therapy. Available studies
have demonstrated that its efficacy is in a similar range to that of conventional CBT.
An online version of acceptance and commitment therapy (ACT) for tinnitus has
been developed as well.97 A comparison between Internet-based ACT (iACT), iCBT,
and a moderated online discussion forum revealed substantial improvements for
both iCBT and iACT, with no significant difference between the 2 treatments.98
With technological advances in the development of smartphones, sound therapy is
an easily accessible treatment option. There are smartphone applications that claim to
reduce tinnitus loudness by the usage of tailor-made notched music (eg, Tinnitracks
[www.tinnitracks.com] or Tinnitus Pro: Music Therapy [https://tinnitus-pro-music-
therapy-ios.soft112.com]).99 One study provided the patients with tinnitus masking
technologies.100 The efficacy of none of these approaches has yet been evaluated.
Further eHealth-based approaches that have been proposed are serious games
and virtual reality.101–103
POTENTIAL NEW DRUG TARGETS
Although many different drugs with different mechanisms of action have been inves-
tigated in the past decades, no drug target could be identified for alleviating either
tinnitus loudness, tinnitus-related distress, or both. Moreover, because there are no
approved drugs for the treatment of tinnitus, there also are no examples of a success-
ful pharmacologic development program that could provide a blueprint for the devel-
opment of a new compound.
Based on an increasing understanding of the pathophysiology of tinnitus, new po-
tential target structures emerged and several candidate drugs for the treatment of
tinnitus have been identified in past years.
Recent clinical research programs that targeted N-methyl-D-aspartate receptor
(NMDA) receptors, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptors, and potassium channels are summarized.
In animal experiments NMDA receptors have been identified to pay a critical role in
the development of salicylate-induced tinnitus.104,105 These findings formed the basis
for the clinical development of the NMDA receptor antagonist Keyzilen (AM-101),
esketamine hydrochloride, by Auris Medical (Basel, Switzerland).
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The intratympanic delivery of a gel formulation of Keyzilen (AM-101) was investi-
gated in patients with acute tinnitus caused by acoustic trauma, idiopathic sudden
sensorineural hearing loss, or otitis media.106 This phase 2 clinical trial failed to
achieve the primary endpoint of improving minimum masking level; however, statisti-
cal significant improvement was demonstrated for tinnitus loudness, annoyance,
sleep difficulties, and tinnitus impact in the high-dose Keyzilen (AM-101) patient
groups with tinnitus after noise trauma or otitis media.106 Based on these findings, a
phase 3 program was initiated, which unfortunately could not confirm the data from
the phase 2 trial.107,108
Another pharmacologic compound, that has been investigated recently (2011–
2012), is BGG492 (selurampanel), which is an orally active AMPA/kainate receptor
antagonist.109 The AMPA receptor has been chosen as target as the main excitatory
activity in both cochlea and the central auditory pathways is AMPA mediated.110
BGG492 was evaluated in patients with moderate to catastrophic chronic subjective
tinnitus. After a 2-week treatment with BGG492, significantly greater proportion of pa-
tients showed response (improvement of 4 points from baseline in Tinnitus Beein-
trächtigungs Fragebogen (TBF-12), a German short version of the Tinnitus Handicap
Inventory) compared with placebo (26.7% vs 14%).111 Due to an unfavorable side-
effect profile, however, BGG492 has not been further developed.
Targeting the central nervous system also has been the focus of AUT00063, a Kv3.1
channel inhibitor. This compound has been investigated in a phase 2a study but was
not superior to placebo in reducing the score of the Tinnitus Functional index.112
Also, Kv7.2/3, another potassium channel, has been proposed as a potential target
for tinnitus treatment. It has been shown that application of the Kv7.2/3 opener retiga-
bine prevents behavioral signs of tinnitus in mice.113 Retigabine was approved in 2011
by the FDA as an adjunctive treatment of partial epilepsies, but the clinical use of reti-
gabine is limited by its side effects. This may explain why this compound has not yet
been investigated in a clinical trial for tinnitus. The promising findings from animal
studies and its availability as an approved drug for epilepsy, however, have motivated
patients to try this potassium channel modulator for tinnitus treatment. Moreover,
some of the patients shared their experiences with this drug via an Internet-based
tinnitus forum.114
An improved Kv7.2/3 activator, the compound SF0034, has been shown to act more
specifically and more potently on Kv7.2/3 channels and to prevent the development of
tinnitus in mice after noise trauma.115 Because SF0034 is less toxic than retigabine, it
might represent a candidate for tinnitus treatment with a more favorable side effect
profile.
Thus, in summary, four different new drug targets have been explored in recent
years. Two studies failed; in 1 case, the development of the compound has not
been continued and a further drug has demonstrated promising results in animal
studies but has not yet been investigated in humans. This illustrates the difficulty in
the development of pharmacologic treatments of tinnitus. A more and more detailed
knowledge about the pathophysiology of tinnitus enables the identification of new po-
tential targets for pharmacologic treatment. With the lack of valid preclinical screening
methods, however, potential new compounds still have to be tested in human pilot tri-
als. The design of human pilot trials for screening promising compounds is not trivial.
First, the definition of inclusion and exclusion criteria is of particular relevance because
of the clinical heterogeneity of tinnitus. Second, the correct estimation of the dose
range and the duration of the treatment is challenging, especially when knowledge
about pharmacokinetics and pharmacodynamics is limited. Third, a sufficiently sensi-
tive instrument for outcome measurement has to be chosen. Therefore, preclinical
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endpoints with validated translation into clinical application would be highly desirable
to improve the risk/benefit balance of preclinical and clinical development of new
compounds for tinnitus treatment.
In summary, despite huge advances in pathophysiologic knowledge and research
methodology in the past decades, pharmaceutical research in tinnitus still represents
a high-risk field. On the other hand, if there were a drug for which a robust effect could
be demonstrated, such a drug would have a huge impact on the field, even if the effect
were small and occurred only in a subgroup of tinnitus patients.
PATIENT INVOLVEMENT
A recent development in tinnitus research is the increasing involvement of tinnitus pa-
tients. Patient representatives were critically involved in recent approaches to identify
patient-relevant outcome measurements.116
Moreover, patient self-organization via the Internet opens up entire new possibilities
compared with traditional patient organizations, because it speeds up interactions
between patients, researchers, and clinicians across borders. For example, the
Internet-based tinnitus forum (tinnitus talk) reaches many thousand patients; via this
forum, patients are informed about newest developments in the field, but they also
can contribute to research, by participating in surveys or by providing the database
for trend analyses of current hot topics.
Recently, the results of a patient survey from tinnitus talk, with more than 5000 par-
ticipants, provided the first empirical confirmation that there exist different tinnitus
subtypes that vary in their response to different therapeutic interventions.31
Finally, in the competition for research money with other research areas, the close
and active interaction between researchers and patients is of utmost importance,
because patient involvement is an increasingly important requirement at more and
more grant agencies.
GRANTS AND FUNDING
Despite the increasing incidence of hearing impairment, funding for research in this
area appears to be significantly under-represented compared with other health prob-
lems of similar relevance.117 If searching specifically for the promotion of tinnitus in the
complex of hearing disorders, a further imbalance becomes apparent. Obviously, a
larger part of the money is spent on research and improvement of technical ap-
proaches, such as cochlear implants and hearing aids. In relation to the large number
of people affected, too little funding remains for tinnitus. This may be explained to a
large extent by the fact that tinnitus is a complex disorder whose exact pathophysi-
ology is not yet clarified in detail and for which there is no causal therapy in most
cases. For the pharmaceutical industry, in particular, these facts seem to represent
a too great risk for large-scale research campaigns. The few pharmaceutical studies
carried out in recent years essentially have been initiated by small companies and
have largely ended with a negative result without corresponding marketing approval,
so that risk appetite will tend to decline. Other funding opportunities are provided by
large self-help institutions, such as the American Tinnitus Association, the British
Tinnitus Association, and the UK Action on Hearing Loss Campaign. In recent years,
a gradual increase in funding has been recorded by these institutions. The funding pro-
vided by state institutions in Europe (German Research Foundation in Germany, Well-
come Trust in the United Kingdom, and Swiss National Science Foundation in
Switzerland) appears to be lower than in the United States (eg, National Institute on
Deafness and Other Communication Disorders). It can be seen, however, that in the
Kleinjung & Langguth10
United States, primarily basic research projects in animal research are funded,
whereas in Europe the focus is on clinical research in tinnitus.117 Thanks to private in-
vestors (often suffering from tinnitus themselves), significant progress has been made
in recent years. Specific funding programs have improved the networking and collab-
oration of scientists in the field of tinnitus. This has led to an enormous increase in pub-
lications in the field of tinnitus, which in turn has improved public perception by funding
institutions. As a result of this development, 2 major projects on tinnitus have been
funded by the European Union in recent years, with a total investment of approxi-
mately $10 million. Within the Innovative Training Networks, including the European
School for Interdisciplinary Tinnitus Research (https://esit.tinnitusresearch.net)118
and Tinnitus Assessment Causes Treatment [https://tinact.eu/]), 30 PhD students
are being trained in tinnitus research. In the future, an important input into tinnitus
research in general can be expected from this.
Together, the efforts of recent years have increased the funding volume in tinnitus
research. In comparison to the frequency of the symptom and the amount of severely
impaired individuals with resulting high socioeconomic burden, however, the invest-
ment for research still seems low.
SUMMARY
In the past decade, various efforts have been made to identify potential new targets20
and to develop innovative auditory, behavioral, pharmacologic, and neuromodulatory
interventions. Moreover, there are ongoing research efforts to refine and validate an-
imal models further,22,119 to develop large clinical databases to address the heteroge-
neity of tinnitus, and to optimize and standardize clinical trial design39 and outcome
measurement tools.36,40 Recently the growing possibilities of eHealth have been
explored for their use in tinnitus, and newmedia facilitate interaction between patients,
researchers, and clinicians of different disciplines. With all these developments,
tinnitus research has reached a state of increasing activity and diversity reflected by
a growing number of publications. It is hoped that these developments soon will
lead to more efficient treatment options for the many patients who currently still suffer
from tinnitus.
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